A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
ConditionAdvanced/Metastatic Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAntengene Biologics Limited
About this trial
This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors
Eligibility criteria
Qualifiers
Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.
Aged at least 18 years as of the date of consent.
Histological or cytological confirmation of a solid tumor, and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or not applicable for standard therapy(ies).
Dose Escalation Phase: all solid tumors.
Disqualifiers
Primary central nervous system disease or central nervous system metastatic disease.
Prior exposure to a Claudin 18.2 targeting agent.
Prior therapy with any chemotherapy, immunotherapy, anticancer agents, or investigational products from a previous clinical study within 28 days of the first dose of study treatment or within a period during which the investigational product or systemic anticancer treatment has not been cleared from the body (eg, a period of 5 'half-lives'.
Prior vaccination within 28 days of the first dose of study therapy.
Trial design
Treatments tested in this trial
- ATG-022
Treatment groups
156 Participants
are divided into 1 treatment groupLocations
22Australia
Cancer Research SA Pty Ltd Adelaide Australia
Cabrini Health Limited Malvern Australia
Integrated Clinical Oncology Network Pty Ltd (Icon) South Brisbane Australia
China
Beijing GoBroad Hospital Beijing China
Sponsors and collaborators
Antengene Biologics Limited
Lead sponsor
Source ClinicalTrials.gov